New Data Suggest Veracyte’s Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results South San Francisco, Calif. --- September 1, 2011 --- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today
New Data Suggest Veracyte's Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples South San Francisco, Calif.--- PRNewswire ---Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, announced that initial
Veracyte Completes $28 Million Series B Round – One Step Closer to Commercializing First Molecular Diagnostic Product SOUTH SAN FRANCISCO, Calif.--- BUSINESS WIRE ---Veracyte, Inc. announced today the successful completion of its Series B round, a key milestone toward the company’s first product
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.